Pharmaceuticals manufacturer Adcock Ingram has reported pressure on its interim revenue and profit as well as a fall in volumes as cash-strapped South Africans cut their discretionary spending on both over-the-counter (OTC) and consumer products.
The group, whose brands include pain killers such as Panado, Gen-Payne and Myprodol, and flu medications such as Corenza-C, also found itself grappling with significant delays at Durban port in the first half of its 2024 year, which affected some key product lines.